NICE to appraise cryoablation and HIFU for prostate cancer
This article was originally published in Clinica
Executive Summary
The UK’s National Institute for Health and Clinical Excellence (NICE) is to appraise two “focal therapy” ablation technologies for the treatment of localised prostate cancer: cryoablation and high-intensity focused ultrasound (HIFU). The appraisals will take place under NICE’s interventional procedures programme, which assesses the efficacy and safety of rarely used or highly innovative techniques, with a view to increasing their use in the NHS. A provisional decision is expected to be issued for consultation in autumn 2011; the provisional publication date is end of 2011 or early-2012.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.